On the evening of March 27, Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) ( Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) ) issued a change announcement to clarify the rumors related to covid-19 drug cooperation. The reporter noted that in addition to Jinglan pharmaceutical, many companies also caused stock price changes due to misinformation related to relevant events, and clarified.
In the announcement, Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) said that in view of the abnormal fluctuation of the company’s stock trading, the company checked the relevant matters and noted that there were rumors on the Internet about ” Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) API with trifluorobenzoyl chloride covid-19″ and ” Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) the only target of the key intermediate of yanyeyi / Pfizer covid-19″.
The company clarified that Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) APIs are mainly quinolones, statins and psychoneurotics. At present, the company and its subsidiaries have not carried out relevant cooperation with yanye Yiyi pharmaceutical and Pfizer pharmaceutical in the aspect of covid-19 drugs. The 2,4,5-trifluorobenzoyl chloride planned by the company’s Shandong base is a key intermediate for the preparation of 2,4,5-trifluorobenzene, and it still needs a certain period to be put into operation, which is expected to have no material impact on the company’s performance in 2022.
On March 24, Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) share price rose sharply in the afternoon, sealed the limit board, opened higher the next day, and soon rose again. As of the closing on the 25th, Jinglan pharmaceutical’s share price closed at 10.53 yuan / share.
The reporter noted that recently, the epidemic concept has continued to strengthen, intermediates / raw materials have the strongest performance, and yanyeyi’s concept has been active. Open source Securities pointed out that yanyeyi covid-19 oral drug s-217622 submitted an application for clinical treatment approval, and the phase 2A clinical results were positive. Among them, after five times of administration, the positive proportion of virus titer in the low-dose s-217622 group was cleared. At present, the raw materials are the focus of the market. According to the analysis of open source securities, one of the main raw materials of covid-19 is 1 – (bromomethyl) – 2,4,5-trifluorobenzene (also known as 3,4,5-trifluorobenzene), which can be obtained by catalytic reduction and bromination of 2,4,5-trifluorobenzaldehyde.
That’s why the share prices of many companies involved in the concept rose sharply. However, some companies clarified that they had been misinformed and related events.
Like Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) , Jiangsu Yabang Dyestuff Co.Ltd(603188) rose the limit for two consecutive days on the 24th and 25th of last week. The company also responded and clarified the rumors about covid-19 in the announcement of stock price changes.
Jiangsu Yabang Dyestuff Co.Ltd(603188) announcement said that the company is concerned about the recent rumors in the market that the company has produced raw materials of covid-19 virus treatment drugs, such as trichlorotoluene and 5-chloro-o-toluidine. After verification, the company does not produce raw materials of covid-19 virus treatment drugs such as trichlorotoluene and 5-chloro-o-toluidine. Trichlorotoluene is the original product of Jiangsu Jiamai Chemical Co., Ltd., the holding subsidiary of the company. Due to the planning adjustment of Jiangsu Lianyungang Port Co.Ltd(601008) chemical park, the company has stopped production and exited, and the relevant devices have been removed. At present, the company is not involved in the production of this product, and has no plan to continue to invest in the project.
Previously, it was rumored on the Internet that Pku Healthcare Corp.Ltd(000788) cooperated with yanyeyi of Japan on covid-19 special drug. The company once had 7 boards in 10 days, and the company also refuted the rumor many times. Peking University Hospital said in a change announcement on March 16 that it had never carried out the research and development of covid-19 specific drugs, nor had it discussed the cooperation of covid-19 specific drugs with yanyeyi, Japan.
Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) was also involved in the hot spot of “yanyeyi covid-19”. Since March 10, the company’s share price has risen sharply Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) is related to yanyeyi of Japan because it is reported that yanyeyi’s covid-19 drug intermediates are mainly polypeptides, and Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) is the main manufacturer of polypeptide intermediates and APIs. It is the only listed company with yanyeyi covid-19 drug intermediate ensitrelvir in the public information.
In this regard, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) clarified that at present, the company has carried out the research and development of intermediates mentioned in the report and has the supply capacity of small batches in the research and development laboratory, but has not carried out commercial production. As of March 15, the company had not provided the above intermediates to yanyeyi pharmaceutical company of Japan.
Earlier this month, Changjiangrunfa Health Industry Co.Ltd(002435) was also involved in the covid-19 oral drug incident in yanyeyi, Japan. The share price rose sharply on March 2 and hit a record high of 9.89 yuan / share on March 14. It closed six daily limits in nine trading days, with an increase of 89.21%. On March 14, Changjiangrunfa Health Industry Co.Ltd(002435) issued an announcement to clarify that although it has reached cooperation with yanyeyi’s chang’ao pharmaceutical on “Lulit” luliconazole cream, the two sides have not carried out cooperation on covid-19 therapeutic drugs. After the clarification announcement was issued, Changjiangrunfa Health Industry Co.Ltd(002435) share price fell.
On the interactive platform, relevant companies also responded one after another.
On March 22, Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) said that regarding the related products of fluorobenzene intermediate 2,4,5-trifluorobenzene, one of the raw materials of oral drugs developed by yanyeyi pharmaceutical for the treatment of covid-19 virus, the company only produced a small number of pilot samples and only provided them to some Chinese customers for testing and trial, but the company did not directly provide samples of the product to yanyeyi pharmaceutical.
On March 18, Zhejiang Yongtai Technology Co .Ltd(002326) said that at present, the company’s fluorobenzene intermediate products include products of difluoro, trifluoro, pentafluoro, hexafluoro, o-fluoro, p-fluoro and other product series, and new products will be developed in time in combination with market demand. 1,2,4-trifluorobenzene can synthesize trifluorobenzene.
\u3000\u3000
